Publications
Access Travere’s peer-reviewed publications.
Results 30
Sort by
Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study
Kidney Failure Attributed to Focal Segmental Glomerulosclerosis: A USRDS Retrospective Cohort Study of Epidemiology, Treatment Modalities, and Economic Burden
Physiologically-based Pharmacokinetic Model of Sparsentan to Evaluate Drug-drug Interaction Potential
Kidney Failure Attributed to Immunoglobulin A Nephropathy: A USRDS Retrospective Cohort Study of Epidemiology, Treatment Modalities, and Economic Burden
Kidney Failure Events, Cardiovascular Disease Events and All-Cause Mortality in Immunoglobulin A Nephropathy Patients in a Real-World Database
Sparsentan Is Superior to Losartan in the gddY Mouse Model 1 of IgA Nephropathy
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis
IgA Nephropathy Patient Baseline Characteristicsin the Sparsentan PROTECT Study
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
Clinicopathological Characteristics of Adult IgA Nephropathy in the United States
Impact of Proteinuria and Kidney Function Decline on Health Care Costs and Resource Utilization in Adults With IgA Nephropathy in the United States: A Retrospective Analysis
Contact Us
For more information, please click on the link below to be directed to our contact us form.
Adverse Event Reporting
To report suspected adverse reactions, contact Travere Therapeutics at 1-877-659-5518 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.